Docking studies on αvβ3 integrin ligands: Pharmacophore refinement and implications for drug design

Journal of Medicinal Chemistry

Volumn 46, Issue 21, 2003, Pages 4393-4404

  Marinelli, Luciana ^a   Lavecchia, Antonio ^b   Gottschalk, Kay E ^a   Novellino, Ettore ^b   Kessler, Horst ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA3 INTEGRIN RECEPTOR; ARGINYLGLYCYLASPARTIC ACID; CILENGITIDE; CYCLOPEPTIDE; INTEGRIN; INTEGRIN RECEPTOR; PENTAPEPTIDE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ARTICLE; CALCULATION; CRYSTAL STRUCTURE; DRUG DESIGN; LIGAND BINDING; PHARMACOPHORE; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS;

EID: 0141958105     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020577m     Document Type: Article

References (75)

1. Hynes, R. O. Integrins: Versatility, Modulation, and Signaling in Cell Adhesion. Cell 1992, 69, 11-25.
2. Humphries, M. J. Integrin structure. Biochem. Soc. Trans. 2000, 28, 311-339.
3. Eble, J. A. Integrin-Ligand Interaction; Springer-Verlag: Heidelberg, 1997; pp 1-40.
4. Ruoslahti, E.; Pierschbacher, M. D. Arg-Gly-Asp- a versatile cell recognition signal. Cell 1986, 44, 517-518.
5. D'Souza, S. E.; Ginsberg, M. H.; Plow, E. F. Arginyl-Glycyl-Aspartic acid (RGD) - a cell-adhesion motif. Trends Biochem. Sci. 1991, 16, 246-250.
6. Aumailley, M.; Gurrath, M.; Müller, G.; Calvete, J.; Timpl, R.; Kessler, H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett. 1991, 291, 50-54.
7. Plow, E. F.; Haas, T. A.; Zhang, L.; Loftus, J.; Smith, J. W. Ligand binding to integrins. J. Biol. Chem. 2000, 275, 21785-21788.
8. 3 for Angiogenesis. Science 1994, 264, 569-571.
9. (b) Ruegg, C.; Dormond, O.; Foletti, A. Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target? Endothelium 2002, 9, 151-160.
10. Reynolds, L. E.; Wyder, L.; Lively, J. C.; Taverna, D.; Robinson, S. D.; Huang, X.; Sheppard, D.; Hynes, R. O.; Hodivala-Dikle, K. M. Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins. Nat. Med. 2002, 8, 27-34.
11. Hynes, R. O. A reevaluation of integrins as regulators of angiogenesis. Nature Med. 2002, 8, 918-921.
12. 3 rescues melanoma-cells from apoptosis in 3-dimensional dermal collagen. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 8856-8860.
13. Ruoslahti, E.; Reed, J. C. Anchorage dependence, integrins, and apoptosis. Cell 1994, 77, 477-478.
14. 3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat. Endocrinology 1996, 137, 918-924.
15. 3 integrin in osteoclast migration and formation of the sealing zone. J. Cell. Sci. 1999, 112, 3985-3993.
16. (b) Kantlehner, M.; Schaffner, P.; Finsinger, D.; Meyer, J.; Jonczyk, A. ; Diefenbach, B.; Nies, B.; Hölzemann, G.; Goodman, S. L.; Kessler, H. Surface coating with cyclic RGD peptides stimulates osteoblast adhesion and proliferation as well as bone formation. ChemBioChem 2000, 1, 107-114.
17. 3 integrin is a negative regulator of angiogenesis is suggested and as a consequence, the drugs targeting it should be considered as agonists rather than antagonists. Although this hypothesis does not dispute the therapeutic potential of the compounds examined here, we will now use the term "ligand" instead of "agonist" or "antagonist".
18. Chorev, M.; Dresnerpollack, R.; Eshel, Y.; Rosenblatt, M. Approach to discovering novel therapeutic agents for osteoporosis based on integrin receptor blockade. Biopolymers 1995, 37, 367-375.
19. 3 integrin inhibits bone-resorption in vitro and prevents osteoporosis in vivo. J. Clin. Invest. 1997, 99, 2284-2292.
20. 3 antagonist. J. Clin. Invest. 1999, 103, 47-54.
21. Seemayer, C. A.; Distler, O.; Kuchen, S.; Muller-Ladner, U.; Michel, B. A.; Neidhart, M.; Gray, R. E.; Gray, S. Rheumatoid arthritis: new developments in the pathogenesis with special reference to synovial fibroblasts. Z. Rheumatol. 2001, 60, 309-318.
22. 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann. Rheum. Dis. 2002, 61 Suppl. 2, ii96-99.
23. (b) Goligorsky, M. S.; Noiri, E.; Kessler, H.; Romanov, V. Therapeutic potential of RGD peptides in acute renal injury. Kidney Int. 1997, 51, 1487-1492.
24. 3 in cell adhesion, motility, and liver metastasis of murine RAW117 large cell lymphoma. Cancer Res. 1996, 56, 3103-3111.
25. 3-targeted therapy for Kaposi's sarcoma with an in vitro-evolved antibody. Faseb. J. 2002, 18, 18.
26. Trikha, M.; Timar, J.; Zacharek, A.; Nemeth, J. A.; Cai, Y.; Dome, B.; Somlai, B.; Raso, E.; Ladanyi, A.; Honn, K. V. Role for beta3 integrins in human melanoma growth and survival. Int. J. Cancer 2002, 101, 156-167.
27. 3 in prostate cancer progression. Neoplasia 2002, 4, 191-194.
28. 3 Antagonists. J. Am. Chem. Soc. 1996, 118, 7461-7472.
29. 1 integrins. J. Biol. Chem. 1994, 269, 20233-20238.
30. 3. Science 2001, 294, 339-345.
31. 3 in Complex with an Arg-Gly-Asp Ligand. Science 2002, 296, 151-155.
32. 3. ChemBioChem 2002, 3, 470-473.
33. Gottschalk, K.-E.; Kessler, H. The Structures of Integrins and Integrin-Ligand Complexes: Implications for Drug Design and Signal Transduction. Angew. Chem., Int. Ed. 2002, 41, 3767-3774.
34. 3 Integrin. J. Med. Chem. 2002, 45, 5640-5648.
35. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
36. Goodsell, D. S.; Morris, G. M.; Olson, A. J. Automated docking of flexible ligands: applications of AutoDock. J. Mol. Recognit. 1996, 9, 1-5.
37. Gurrath, M.; Müller, G.; Kessler, H.; Aumailley, M.; Timpl, R. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. Eur. J. Biochem. 1992, 210, 911-921.
38. 3 Integrin for a New Cancer Therapy. Angew. Chem., Int. Ed. 1997, 36, 1374-1389.
39. 3 Integrin Antagonists. J. Med. Chem. 1999, 42, 3033-3040.
40. Peishoff, C. E.; Ali, F. E.; Bean, J. W.; Calvo, R.; D'Ambrosio, C. A.; Eggleston, D. S.; Hwang, S. M.; Kline, T. P.; Koster P. F.; Nichols, A.; Powers, D.; Romoff, T.; Samanen, J. M.; Stadel, J.; Vasko, J.; Kopple, K. D. Investigation of conformational specificity at GPIIb/IIIa: evaluation of conformationally constrained RGD peptides. J. Med. Chem. 1992, 35, 3962-3969.
41. Kopple, K. D.; Baures, P. W.; Bean, J. W.; D'Ambrosio, C. A.; Hughes, J. L.; Peishoff, C. E.; Eggleston, D. S. Conformations of Arg-Gly-Asp Containing Heterodetic Cyclic Peptides: Solution and Crystal Studies. J. Am. Chem. Soc. 1992, 114, 9615-9623.
42. (a) Haubner, R.; Schmitt, W.; Hölzemann, G.; Goodman, S. L.; Jonczyk, A.; Kessler, H. Cyclic RGD Peptides Containing β-Turn Mimetics. J. Am. Chem. Soc. 1996, 118, 7881-7891.
43. (b) Belvisi, L.; Bernardi, A.; Checchia, A.; Manzoni, L.; Potenza, D.; Scolastico, C.; Castorina, M.; Cupelli, A.; Giannini, G.; Carminati, P.; Pisano, C. Potent integrin antagonists from a small library of RGD-including cyclic pseudopeptides. Org. Lett. 2001, 3, 1001-1004.
44. v-Selective RGD Peptides. Angew. Chem., Int. Ed. 2000, 39, 2761-2764.
45. (b) Sukopp, M.; Marinelli, L.; Heller, M.; Brandl, T.; Goodman, S. L.; Hoffmann, R. W.; Kessler, H. Designed Beta-turn Mimic based on the Allylic Strain Concept: Evaluation of Structural and Biological Features by Incorporation into a Cyclic RGD-Peptide. Helv. Chim. Acta 2002, 85, 4442-4452.
46. 3 Integrin Inhibitor cyclo(-RGDfV-) and Its Retro-Inverso Peptide. J. Am. Chem. Soc. 1997, 119, 1328-1335.
47. 3. J. Med. Chem. 2000, 43, 27-40.
48. 3 antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptide. Bioorg. Med. Chem. Lett. 2002, 12, 25-29.
49. 3 Antagonist. J. Med. Chem. 2000, 43, 3736-3745.
50. 3. J. Med. Chem. 2000, 43, 41-58.
51. Nicolaou, K. C.; Trujillo, J. T.; Janderleit, B.; Chibale, K.; Rosenfeld, M.; Diefenbach, B.; Cheresh, D. A.; Goodman, S. L. Design, synthesis and biological evaluation of nonpeptide integrin antagonists. Bioorg. Med. Chem. 1998, 6, 1185-1208.
52. 3) Antagonists. J. Med. Chem. 1997, 40, 2289-2292.
53. 3) antagonists. Bioorg. Med. Chem. Lett. 1998, 8, 3165-3170.
54. Miller, W. H.; Alberts, D. P.; Callahan, P. K.; Calvo, R. R.; Cousins, R. D.; Erhard, K. F.; Heerding, D. A.; Keenan, R. M.; Kwon, C.; Manley, P.; Newlander, A. K.; Ross, S. T.; Samanen, J. M.; Uzinskas, I. N.; Venslavsky, J. W.; Yuan, C.-K.; Haltiwanger, R. C.; Gowen, M.; Hwang, S.-M.; James, I. E.; Lark, M. W.; Rieman, D. J.; Stroup, G. B.; Smith, B. R.; Ward, K. W.; Johanson, K. O.; Huffman, W. Discovery of orally active nonpeptide vitronectin antagonists based on a 2-Benzazepine Gly-Asp mimetic. J. Med. Chem. 2000, 43, 22-26.
55. 3 Integrin Antagonists. J. Med. Chem. 2001, 44, 1938-1950.
56. 3 Integrin Antagonist libraries: On-Bead Screening and Mass Spectrometric Identification without Tagging. Angew. Chem., Int. Ed. 2001, 40, 165-169.
57. 3 Integrins. J. Med. Chem. 2002, 45, 1045-1051.
58. SYBYL Molecular Modeling System (version 6.8), TRIPOS Assoc., St. Louis, MO.
59. Head, J.; Zerner, M. C. A Broyden-Fletcher-Goldfarb-Shanno Optimization Procedure for Molecular Geometries. Chem. Phys. Lett. 1985, 122, 264-274.
60. Vinter, J. G.; Davis, A.; Saunders: M. R. Strategic Approaches to Drug Design. 1. An Integrated Software Framework for Molecular Modelling. J. Comput.-Aided Mol. Design 1987, 1, 31-55.
61. (a) MOPAC (version 6.0) is available from Quantum Chemistry Program Exchange, No. 455.
62. (b) Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. AM1: a New General Purpose Mechanical Molecular Model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
63. Allen, F. H.; Bellard, S.; Brice, M. D.; Cartwright, B. A.; Doubleday: A.; Higgs, H.; Hummelink, T.; Hummelink-Peters, B. G.; Kennard, O.; Motherwell, W. D. S.; The Cambridge Crystallographic Data Centre: Computer-Based Search, Retrieval, Analysis and Display of Information. Acta Crystallogr. 1979, B35, 2331-2339.
64. (a) Chakravorty, S.; Reynolds, C. H. Improved AMBER torsional parameters for the N-N rotational barrier in diacylhydrazines. J. Mol. Graph. Model. 1999, 17, 315-324.
65. (b) Günther, R.; Hofmann, H. J. Hydrazino peptides as foldamers: an extension of the beta-peptide concept. J. Am. Chem. Soc. 2001, 123, 247-255.
66. (a) DISCOVER, Version 95.0; BIOSYM Technologies, 10065 Barnes Canyon Rd, San Diego, CA 92121.
67. (b) Hagler, A. F.; Lifson, S.; Dauber, P. Consistent force field studies of intermolecular forces in hydrogen-bonded crystals. J. Am. Chem. Soc. 1979, 101, 5122-5130.
68. Bogusy, M. J.; Naylor, A. M.; Pitzenberger, S. M.; Nutt, R. F.; Brady, S. F.; Colton, C. D.; Sisko, J. T.; Anderson, P. S.; Veber, D. F. NMR and molecular modeling characterization of RGD containing peptides. J. Pep. Prot. Res. 1992, 39, 63-76.
69. Bogdanowich-Knipp, S. J.; Jois, D. S. S.; Siahaan, T. J. The effect of conformation on the solution stability of linear vs cyclic RGD peptides. J. Pept. Protein Res. 1999, 53, 523-529.
70. Yamanouchi, J.; Hato, T.; Tamura, T.; Fujita, S. Identification of critical residues for ligand binding in the integrin beta3 I-domain by site-directed mutagenesis. Thromb. Haemost. 2002, 87, 756-762.
71. 3 is dependent on a MIDAS-like domain in the beta3 subunit. J. Biol. Chem. 1996, 271, 21978-21984.
72. v subunit. Blood 2001, 97, 175-182.
73. 3 Integrin: A Photoaffinity Cross-Linking Study. Biochemistry 2002, 41, 8321-8331.
74. 2+ binding site on the beta3-integrins that regulates the dissociation rate for RGD ligands. J. Biol. Chem. 1996, 271, 21745-21751.
75. Arnaout, M. A.; Goodman, S. L.; Xiong, J. P. Coming to grips with integrin binding to ligands. Curr. Opin. Cell. Biol. 2002, 14, 641-651.